Genomic Landscape and Expression Profile of Consensus Molecular Subtype Four of Colorectal Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 5

PMID 37404825

Authors

Yujie Lu

Dingyi Gu

Chenyi Zhao

Ying Sun

Wenjing Li

Lulu He

Xiaoyan Wang

Zhongyang Kou

Jiang Su

Feng Guo

Affiliations

Soon will be listed here.

Abstract

Background: Compared to other subtypes, the CMS4 subtype is associated with lacking of effective treatments and poorer survival rates.

Methods: A total of 24 patients with CRC were included in this study. DNA and RNA sequencing were performed to acquire somatic mutations and gene expression, respectively. MATH was used to quantify intratumoral heterogeneity. PPI and survival analyses were performed to identify hub DEGs. Reactome and KEGG analyses were performed to analyze the pathways of mutated or DEGs. Single-sample gene set enrichment analysis and Xcell were used to categorize the infiltration of immune cells.

Results: The CMS4 patients had a poorer PFS than CMS2/3. and were common mutated genes in the CMS4 subtype, which were enriched in Wnt and cell cycle signaling pathways, respectively. The MATH score of CMS4 subtype was lower. was a hub DEG. M2 macrophages were more infiltrated in the tumor microenvironment of CMS4 subtype. The CMS4 subtype tended to have an immunosuppressive microenvironment.

Conclusion: This study suggested new perspectives for exploring therapeutic strategies for the CMS4 subtype CRC.

Citing Articles

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges.

Dang Q, Zuo L, Hu X, Zhou Z, Chen S, Liu S Cancer Med. 2024; 13(14):e70041.

PMID: 39054866 PMC: 11272957. DOI: 10.1002/cam4.70041.

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies.

Kiran N, Yashaswini C, Maheshwari R, Bhattacharya S, Prajapati B ACS Pharmacol Transl Sci. 2024; 7(4):967-990.

PMID: 38633600 PMC: 11019743. DOI: 10.1021/acsptsci.4c00008.

Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study.

Messaritakis I, Psaroudaki E, Vogiatzoglou K, Sfakianaki M, Topalis P, Iliopoulos I Cancers (Basel). 2023; 15(19).

PMID: 37835512 PMC: 10571744. DOI: 10.3390/cancers15194819.

References

Stahler A, Hoppe B, Na I, Keilholz L, Muller L, Karthaus M . Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). J Clin Oncol. 2023; 41(16):2975-2987. DOI: 10.1200/JCO.22.02582. View

Sawayama H, Miyamoto Y, Ogawa K, Yoshida N, Baba H . Investigation of colorectal cancer in accordance with consensus molecular subtype classification. Ann Gastroenterol Surg. 2020; 4(5):528-539. PMC: 7511559. DOI: 10.1002/ags3.12362. View

Wilhelm S, Dumas J, Adnane L, Lynch M, Carter C, Schutz G . Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2010; 129(1):245-55. DOI: 10.1002/ijc.25864. View

Mao C, Yang Z, Hu X, Chen Q, Tang J . PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2011; 23(6):1518-25. DOI: 10.1093/annonc/mdr464. View

Zhou K, Shi H, Chen R, Cochuyt J, Hodge D, Manochakian R . Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Netw Open. 2021; 4(1):e2032276. PMC: 7804918. DOI: 10.1001/jamanetworkopen.2020.32276. View

Rai S, Mishra P, Ghoshal U . Survival analysis: A primer for the clinician scientists. Indian J Gastroenterol. 2022; 40(5):541-549. PMC: 8743691. DOI: 10.1007/s12664-021-01232-1. View

Trinh A, Ladrach C, Dawson H, Ten Hoorn S, Kuppen P, Reimers M . Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. Br J Cancer. 2018; 119(10):1244-1251. PMC: 6251036. DOI: 10.1038/s41416-018-0230-7. View

Arai H, Battaglin F, Wang J, Lo J, Soni S, Zhang W . Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019; 81:101912. PMC: 7491975. DOI: 10.1016/j.ctrv.2019.101912. View

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

10.

Adams E . Diverse antigen presentation by the Group 1 CD1 molecule, CD1c. Mol Immunol. 2012; 55(2):182-5. PMC: 3612385. DOI: 10.1016/j.molimm.2012.10.019. View

11.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

12.

Mishra S, Bernal C, Silvano M, Anand S, Ruiz i Altaba A . The protein secretion modulator TMED9 drives CNIH4/TGFα/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases. Oncogene. 2019; 38(29):5817-5837. PMC: 6755966. DOI: 10.1038/s41388-019-0845-z. View

13.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

14.

Ueda S, Hayashi H, Miyamoto T, Abe S, Hirai K, Matsukura K . Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes. Cancer Sci. 2018; 110(2):674-685. PMC: 6361610. DOI: 10.1111/cas.13908. View

15.

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

16.

Sparks A, Morin P, Vogelstein B, Kinzler K . Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58(6):1130-4. View

17.

Ni L, Dong C . New B7 Family Checkpoints in Human Cancers. Mol Cancer Ther. 2017; 16(7):1203-1211. PMC: 5568666. DOI: 10.1158/1535-7163.MCT-16-0761. View

18.

Mroz E, Tward A, Tward A, Hammon R, Ren Y, Rocco J . Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015; 12(2):e1001786. PMC: 4323109. DOI: 10.1371/journal.pmed.1001786. View

19.

Jackstadt R, van Hooff S, Leach J, Cortes-Lavaud X, Lohuis J, Ridgway R . Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer Cell. 2019; 36(3):319-336.e7. PMC: 6853173. DOI: 10.1016/j.ccell.2019.08.003. View

20.

Lim S, Chua M, Yeong J, Tan S, Lim W, Lim C . Pan-cancer analysis connects tumor matrisome to immune response. NPJ Precis Oncol. 2019; 3:15. PMC: 6531473. DOI: 10.1038/s41698-019-0087-0. View